Search

1 to 10 of 153
Sort by

Library Entry
Gal9/Tim-3 expression level is higher in AML patients who fail chemotherapy

Immune checkpoint pathways active in Acute Myeloid Leukemia (AML) patients, especially during the course of remission induction chemotherapy, have not been well studied. Although dominant in mediating T cell dysfunction in cancer, it is now well-accepted that interruption of PD-1/PD-L1 axes...


Library Entry
Plasmacytoid dendritic cells orchestrate innate and adaptive anti-tumor immunity induced by oncolytic coxsackievirus A21

The oncolytic virus, coxsackievirus A21 (CVA21), has shown promise as a single agent in several clinical trials and is now being tested in combination with immune checkpoint blockade. Combination therapies offer the best chance of disease control; however, the design of successful combination...



Library Entry
Opportunities and challenges of active immunotherapy in dogs with B-cell lymphoma: a 5-year experience in two veterinary oncology centers

Published in the Journal for ImmunoTherapy of Cancer (JITC), is a research article concluding that the addition of immunotherapy to a traditional CHOP protocol is associated with improved outcome in dogs with B-cell lymphoma, regardless of histotype and evaluated prognostic factors. Moreover,...


Library Entry
Bispecific NKG2D-CD3 and NKG2D-CD16 fusion proteins for induction of NK and T cell reactivity against acute myeloid leukemia

Published in the Journal for ImmunoTherapy of Cancer (JITC), is a research article introducing novel “antibody-like” BFP that takes advantage of the highly tumor-restricted expression of NKG2DL and potently activates the reactivity of NK cells or T cells for immunotherapy of AML. Authors: ...



Library Entry
STIM1 at the plasma membrane as a new target in progressive chronic lymphocytic leukemia

Published in the Journal for ImmunoTherapy of Cancer (JITC), is a research article establishing the critical role of a newly discovered BCR independent Ca 2+ entry in CLL evolution, providing new insights into CLL pathophysiology, and supporting innovative therapeutic perspectives such as...